VIFOR-PHARMA-GROUP
26.4.2022 17:47:11 CEST | Business Wire | Press release
Regulatory News:
At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.
Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd. and the consolidated Financial Statements of Vifor Pharma for 2021 by a large majority, as well as the 2021 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2021. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 3 May 2022 on.
Re-election of Board of Directors
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Hon. Dr. Michel Burnier, Dr. Romeo Cerutti, Dr. Alexandre LeBeaut, Dr. Sue Mahony, Åsa Riisberg and Kim Stratton in office, as well as Dr. Sue Mahony (Chair), Prof. Hon. Dr. Michel Burnier and Dr. Romeo Cerutti to the Remuneration Committee.
Conditional new elections to the Board, effective as from settlement date
In addition, the Annual General Meeting conditionally elected Paul McKenzie (elected Chairman), Greg Boss, John Levy, Joy Linton, Markus Stämpfli and Elizabeth Walker as new members of the Board of Directors, to become effective as from the date of settlement under the terms of the tender offer of CSL Behring AG as of 18 January 2022. Greg Boss, Joy Linton and Elizabeth Walker have been conditionally elected to the Remuneration Committee.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005779/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day14.10.2026 12:30:00 CEST | Press release
First-ever Treatment-Resistant Depression (TRD) Awareness Day establishes dedicated moment to recognize and raise awareness of the condition’s profound impact on patients and their loved ones Survey data in a new report highlighting the significant burden of TRD on patients and caregivers to be released in a future communication Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAMI), Mental Health America (MHA) and the Depression and Bipolar Support Alliance (DBSA). TRD is a form of depression distinct from major depressive disorder (MDD) that is estimated to affect approximately 4 million people in the U.S.,
Reliance Foundation and The Estée Lauder Companies Charitable Foundation Launch Multi-Year Partnership That Aims to Empower One Million Girls and Young Women in India14.10.2026 12:10:00 CEST | Press release
Partnership brings together two organizations with a shared commitment to advancing progress for women and girls. Reliance Foundation and The Estée Lauder Companies Charitable Foundation, the philanthropic arm of The Estée Lauder Companies, have announced the launch of a multi-year partnership that aims to empower one million girls and young women across India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014635257/en/ Mr. Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies, and President, The Estée Lauder Companies Charitable Foundation, and Ms. Isha Ambani, Director, Reliance Foundation. The program is designed for girls and young women from 14 to 20 years of age, across both rural and urban communities, with a focus on building life skills and confidence. It will begin in the Indian states of Maharashtra and Madhya Pradesh, with plans to expand to other parts of the country in th
High-Capacity DDoS Attacks Surge 1,286% in 1H 2026 According to NETSCOUT Threat Intelligence Research14.10.2026 12:05:00 CEST | Press release
Massive 1Tbps Events and Weaponized Residential Proxies Expose Critical Mitigation Gaps, Forcing Organizations to Rethink Enterprise and Carrier Defenses NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT) released its first half 2026 Distributed Denial-of-Service (DDoS) Threat Intelligence Report, revealing a significant shift in how attacks are launched and sourced. With more than 9.1 million DDoS attacks recorded globally by NETSCOUT between January and June 2026, the report highlights that DDoS risk is growing along three axes: the volume of traffic that must be inspected, the number of places where mitigation must be deployed, and the share of attacks that disrupt service without ever saturating a link. “The 1,286% rise in attacks clearing 1Tbps or 1Gpps means high-capacity events are no longer anomalies; they are routine,” stated Hardik Modi, VP Engineering, DDoS Solutions, and ASERT Threat Intelligence Team, NETSCOUT. “With the proliferation of residential proxies and short, rate-based attac
Reply Introduces Symbiosis: an AI-Driven Operating Model to Align Business Priorities and AI-Accelerated Delivery14.10.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014833053/en/ Reply introduces Symbiosis, an AI-driven operating model designed for enterprises integrating generative AI and agentic systems into their operating processes. Supported by a dedicated platform, Symbiosis connects strategy, portfolio management and execution, helping organisations align priorities and investment decisions with measurable business outcomes. As AI enables teams to develop, test and deliver solutions faster, organisations also need to adapt how they decide where to focus that cap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom